Literature DB >> 12224000

Overview of 321 patients with idiopathic thrombocytopenic purpura. Retrospective analysis of the clinical features and response to therapy.

G E Pamuk1, O N Pamuk, Z Başlar, S Ongören, T Soysal, B Ferhanoğlu, Y Aydin, B Ulkü, G Aktuğlu, N Akman.   

Abstract

In this retrospective study, we evaluated the clinical features and the effects of various treatment modalities on the clinical course in patients diagnosed with idiopathic thrombocytopenic purpura (ITP) at our center between 1984-2000. We retrospectively examined the medical records of 321 (229 females, 92 males) ITP patients. One hundred and seventy-one (53.3%) patients were lost to follow-up. When evaluating the clinical features, all 321 patients were included; however, when the response to treatment modalities was evaluated only 150 patients followed up regularly were considered. The median age of the patients on initial diagnosis was 34 years (range: 14-78). At initial diagnosis, 235 (73.2%) patients had signs of bleeding. Of patients diagnosed with ITP initially, six later turned out to have systemic lupus erythematosus (SLE) and two myelodysplastic syndrome (MDS). The median follow-up of 150 patients followed up regularly was 30 months (range: 4-396). One hundred and thirty-seven of these subjects had an indication for treatment and 94.2% of them were administered either standard or high-dose steroids as the first-line therapy. Complete remission (CR) was defined as any platelet count >100,000/mm(3) lasting for 3 months or longer without treatment. CR was achieved in 51.9% of the patients given steroids as the initial therapy. During a median follow-up of 33 months, relapse occurred in 58.2% of these patients, and after a median follow-up of 11 months the rest of them were still in remission. Ninety-eight patients followed up regularly were administered second-line therapies. CR was obtained in 44.4% of the patients who used steroids as second-line therapy. Within a median follow-up of 15 months, 20.8% of these patients relapsed. Splenectomy was performed in 76 patients and CR was obtained in 68.4% of the regularly followed up patients. Relapse occurred within a median of 96 months in 15.4% of the patients who had CR. Kaplan-Meier curves showed that the duration of CR obtained by splenectomy was significantly higher than that obtained by steroids (p<0.001). The 10-year disease-free survivals in patients who used steroids and who underwent splenectomy were, respectively, 13% and 58%. In our adult ITP patients, steroids induced nearly similar rates of CR both as first-and second-line therapies. Splenectomy seems to be effective in patients unresponsive to steroids. The duration of CR obtained by splenectomy is significantly longer when compared with the duration of CR obtained by steroid therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12224000     DOI: 10.1007/s00277-002-0488-x

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  13 in total

1.  Pediatric lupus--are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus?

Authors:  Rina Mina; Hermine I Brunner
Journal:  Rheum Dis Clin North Am       Date:  2010-02       Impact factor: 2.670

2.  [Primary immune thrombocytopenia in adults: diagnostics and treatment consensus statement of the Austrian Society of Hematology and Oncology (ÖGHO)].

Authors:  Ingrid Pabinger; Günther Gastl; Michael Steurer; Siegfried Sormann; Michael Fillitz; Josef Friedl; Dietmar Geissler; Klaus Geissler; Richard Greil; Paul Knöbl; Sibylle Kozek-Langenecker; Peter Krippl; Paul Kyrle; Alois Lang; Werner Linkesch; Heinz Ludwig; Markus Müller; Simon Panzer; Elisabeth Pittermann; Josef Thaler; Ansgar Weltermann
Journal:  Wien Klin Wochenschr       Date:  2012-03-03       Impact factor: 1.704

3.  Refractory thrombocytopenia, an unusual myelodysplastic syndrome with an initial presentation mimicking idiopathic thrombocytopenic purpura.

Authors:  Jun Qian; Yongquan Xue; Jinlan Pan; Jiannong Cen; Wei Wang; Zixing Chen
Journal:  Int J Hematol       Date:  2005-02       Impact factor: 2.490

4.  Efficacy and steroid-sparing effect of tacrolimus in patients with autoimmune cytopenia.

Authors:  Ruoxi Zhang; Miao Chen; Chen Yang; Bing Han
Journal:  Ann Hematol       Date:  2022-09-06       Impact factor: 4.030

5.  Treatment of patients with immune thrombocytopenia admitted to the emergency room.

Authors:  Işıl Bavunoğlu; Ahmet Emre Eşkazan; Muhlis Cem Ar; Mahir Cengiz; Serap Yavuzer; Ayşe Salihoğlu; Şeniz Öngören; Aydın Tunçkale; Teoman Soysal
Journal:  Int J Hematol       Date:  2016-04-29       Impact factor: 2.490

Review 6.  Idiopathic thrombocytopenic purpura: a retrospective analysis in 139 patients of the influence of age on the response to corticosteroids, splenectomy and danazol.

Authors:  Emmanuel Andrès; Jacques Zimmer; Esther Noel; Georges Kaltenbach; Argyro Koumarianou; Frédéric Maloisel
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 7.  [Autoimmune thrombocytopenia, neutropenia and hemolysis].

Authors:  A Greinacher; J Bux; A Salama
Journal:  Internist (Berl)       Date:  2009-03       Impact factor: 0.743

8.  Contributions of T lymphocyte abnormalities to therapeutic outcomes in newly diagnosed patients with immune thrombocytopenia.

Authors:  Zhenhua Zhao; Lei Yang; Guohua Yang; Yun Zhuang; Xifeng Qian; Xin Zhou; Dajiang Xiao; Yunfeng Shen
Journal:  PLoS One       Date:  2015-05-15       Impact factor: 3.240

9.  A case of refractory thrombocytopenia with 5q deletion: myelodysplastic syndrome mimicking idiopathic thrombocytopenic purpura.

Authors:  Jeonghyun Chang; Chan-Jeoung Park; Eul-Ju Seo; Jung-Hee Lee; Sang Hyuk Park; Young-Uk Cho; Seongsoo Jang
Journal:  Ann Lab Med       Date:  2014-10-28       Impact factor: 3.464

10.  Late results after splenectomy in adult idiopathic thrombocytopenic purpura.

Authors:  Rosario Vecchio; Eva Intagliata; Francesco La Corte; Salvatore Marchese; Rossella R Cacciola; Emma Cacciola
Journal:  JSLS       Date:  2015 Jan-Mar       Impact factor: 2.172

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.